Advertisement
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1. Harkness JE, Murray KA, Wagner JE. Biology and diseases of guinea pigs. In: Fox JG, Anderson LC, Loew FM, et al, eds. Laboratory animal medicine. 2nd ed. San Diego: Academic Press, 2002;203–204.
-
2. DeCubellis J. Common emergencies in rabbits, guinea pigs, and chinchillas. Vet Clin North Am Exot Anim Pract 2016;19:411–429.
-
3. Hawkins MG. The use of analgesics in birds, reptiles, and small exotic mammals. J Exot Pet Med 2006;15:177–192.
-
4. Flecknell P. Analgesics in small mammals. Vet Clin North Am Exot Anim Pract 2018;21:83–103.
-
5. Houck EL, Guzman DS, Beaufrère H, et al. Evaluation of the thermal antinociceptive effects and pharmacokinetics of hydromorphone hydrochloride after intramuscular administration to cockatiels (Nymphicus hollandicus). Am J Vet Res 2018;79:820–827.
-
6. KuKanich B, Hogan BK, Krugner-Higby LA, et al. Pharmakokinetics of hydromorphone hydrochloride in healthy dogs. Vet Anaesth Analg 2008;35:256–264.
-
7. Wegner K, Robertson SA, Kollias-Baker C, et al. Pharmacokinetics and pharmacodynamic evaluation of intravenous hydromorphone in cats. J Vet Pharmacol Ther 2004;27:329–336.
-
8. Pettifer G, Dyson D. Hydromorphone: A cost-effective alternative to the use of oxymorphone. Can Vet J 2000;41:135–1 3 7.
-
9. Jeleazcov C, Saari TI, Ihmsen H, et al. Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. Anesthesiology 2014;120:378–391.
-
10. Guedes AG, Papich MG, Rude EP, et al. Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs. J Vet Pharmacol Ther 2008;31:334–343.
-
11. Sadar MJ, Knych HK, Drazenovich TL, et al. Pharmacokinetics of buprenorphine after intravenous and oral transmucosal administration in guinea pigs (Cavia Porcellus). Am J Vet Res 2018;79:260–266.
-
12. Pypendop BH, Ilkiw JE, Shilo-Benjamini Y. Bioavailibility of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. J Vet Pharmacol Ther 2014;37:295–300.
-
13. Reed R, Barletta M, Mitchell K, et al. The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. Vet Anaesth Analg 2019;46:395–404.
-
14. Kelly KR, Pypendop BH, Christe KL. Pharmacokinetics of hydromorphone after intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta). J Am Assoc Lab Anim Sci 2014;53:512–516.
-
15. Toutain PL, Bousquet-Melou A. Bioavailability and its assessment. J Vet Pharmacol Ther 2004;27:455–466.
-
16. Gabrielsson J, Hjorth S. Physiological variables of 11 animal species and man. In: Quantitative pharmacology: an introduction to integrative pharmacokinetic-pharmacodynamic analysis. Stockholm: Swedish Pharmaceutical Press, 2012;225–227.
-
17. Reidenberg MM, Goodman H, Erle H, et al. Hydromorphone levels and pain control in patients with severe chronic pain. Clin Pharmacol Ther 1988;44:376–382.
-
18. Zheng M, McErlane KM, Ong MC. LC-MS-MS analysis of hydromorphone and hydromorphone metabolites with application to a pharmacokinetic study in male Spraque-Dawley rat. Xenobiotica 2002;32:141–151.
-
19. Zheng M, McErlane KM, Ong MC. Hydromorphone metabolites: isolation and identification from pooled urine samples of a cancer patient. Xenobiotica 2002;32:427–439.
-
20. Wright AW, Mather ML, Smith MT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001;69:409–420.
-
21. Zheng M, McErlane KM, Ong MC. Identification and synthesis of norhydromorphone, and determination of antinociceptive activities in the rat formalin test. Life Sci 2004;75:3129–3146.
Advertisement
Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration in guinea pigs (Cavia porcellus)
Abstract
OBJECTIVE
To determine the pharmacokinetics of hydromorphone hydrochloride after IV and IM administration in guinea pigs (Cavia porcellus).
ANIMALS
8 healthy adult guinea pigs (4 sexually intact females and 4 sexually intact males).
PROCEDURES
In a crossover study, hydromorphone (0.3 mg/kg) was administered once IM (epaxial musculature) or IV (cephalic catheter) to each guinea pig at a 1-week interval (2 treatments/guinea pig). Blood samples were collected before and at predetermined intervals after drug administration via a vascular access port. Plasma hydromorphone concentrations were determined by liquid chromatography–tandem mass spectrometry. Noncompartmental analysis of data was used to calculate pharmacokinetic parameters.
RESULTS
Mean ± SD clearance and volume of distribution for hydromorphone administered IV were 52.8 ± 13.5 mL/min/kg and 2.39 ± 0.479 L/kg, respectively. Mean residence time determined for the IV and IM administration routes was 0.77 ± 0.14 hours and 0.99 ± 0.34 hours, respectively. The maximum observed plasma concentration following IM administration of hydromorphone was 171.9 ± 29.4 ng/mL. No sedative effects were observed after drug administration by either route.
CONCLUSIONS AND CLINICAL RELEVANCE
Pharmacokinetic data indicated that hydromorphone at a dose of 0.3 mg/kg may be administered IV every 2 to 3 hours or IM every 4 to 5 hours to maintain a target plasma concentration between 2 and 4 ng/mL in guinea pigs. Hydromorphone had high bioavailability after IM administration. Further research is necessary to evaluate the effects of other doses and administration routes and the analgesic effects of hydromorphone in guinea pigs.
Contributor Notes
Powered by PubFactory